These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Mehta J; Powles R; Singhal S; Iveson T; Treleaven J; Catovsky D Bone Marrow Transplant; 1996 Mar; 17(3):371-5. PubMed ID: 8704689 [TBL] [Abstract][Full Text] [Related]
29. The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia. Davids MS; Alyea EP Curr Hematol Malig Rep; 2015 Mar; 10(1):18-27. PubMed ID: 25682168 [TBL] [Abstract][Full Text] [Related]
30. Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia. Santos ES; Masri M; Safah H Expert Rev Anticancer Ther; 2005 Oct; 5(5):875-91. PubMed ID: 16221057 [TBL] [Abstract][Full Text] [Related]
31. [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia]. Liu QF; Sun J; Xu D; Zhang Y; Fan ZP; Wei YQ; Meng FY; Zhou SY Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1117-9. PubMed ID: 15485779 [TBL] [Abstract][Full Text] [Related]
32. Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality--a single institution experience. Chakupurakal G; Leitzke S; Langerbeins P; Schiller J; Schneider PM; Holtick U; Shimabukuro-Vornhagen A; Theurich S; Chemnitz J; Hallek M; von Bergwelt-Baildon M; Scheid C Ann Hematol; 2015 Oct; 94(10):1717-25. PubMed ID: 26259502 [TBL] [Abstract][Full Text] [Related]
33. The role of stem cell transplantation in the treatment of chronic lymphocytic leukemia. Dreger P; Schmitz N Leukemia; 1997 Apr; 11 Suppl 2():S42-5. PubMed ID: 9178838 [TBL] [Abstract][Full Text] [Related]
34. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121 [TBL] [Abstract][Full Text] [Related]
35. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party. Kataoka I; Kami M; Takahashi S; Kodera Y; Miyawaki S; Hirabayashi N; Okamoto S; Matsumoto N; Miyazaki Y; Morishita Y; Asai O; Maruta A; Yoshida T; Imamura M; Hamajima N; Matsuo K; Harada M; Mineishi S; Bone Marrow Transplant; 2004 Oct; 34(8):711-9. PubMed ID: 15361916 [TBL] [Abstract][Full Text] [Related]
36. The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial). Montesinos P; Cabrero M; Valcárcel D; Rovira M; García-Marco JA; Loscertales J; Moreno C; Duarte R; Terol MJ; Villamor N; Abrisqueta P; Caballero D; Sanz J; Delgado J Bone Marrow Transplant; 2016 Oct; 51(10):1404-1407. PubMed ID: 27214073 [No Abstract] [Full Text] [Related]